Morgan Stanley Reiterates CHF 260 Price Target for Roche Holding Ltd. (ROG)
Roche Holding Ltd. (VTX:ROG) received a CHF 260 target price from stock analysts at Morgan Stanley in a report released on Friday. The brokerage presently has a “neutral” rating on the healthcare company’s stock.
Several other equities analysts have also weighed in on the stock. Goldman Sachs Group, Inc. (The) set a CHF 325 price target on shares of Roche Holding and gave the company a “buy” rating in a research report on Monday, September 11th. Credit Suisse Group set a CHF 300 price target on shares of Roche Holding and gave the company a “buy” rating in a research report on Monday, September 11th. Citigroup Inc. restated a “buy” rating on shares of Roche Holding in a research report on Wednesday, July 5th. Societe Generale set a CHF 275 price target on shares of Roche Holding and gave the company a “neutral” rating in a research report on Thursday, June 29th. Finally, Baader Bank set a CHF 231 price target on shares of Roche Holding and gave the company a “neutral” rating in a research report on Tuesday, September 12th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the company’s stock. Roche Holding currently has a consensus rating of “Hold” and a consensus price target of CHF 263.81.
Roche Holding (VTX ROG) traded down 2.10% during mid-day trading on Friday, hitting CHK 233.60. 2,772,893 shares of the stock were exchanged. Roche Holding has a 52 week low of CHK 218.30 and a 52 week high of CHK 273.00. The stock’s 50-day moving average is CHK 245.36 and its 200 day moving average is CHK 250.97. The company has a market capitalization of CHK 199.32 billion and a PE ratio of 20.74.
TRADEMARK VIOLATION NOTICE: This report was reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/10/20/morgan-stanley-reiterates-chf-260-price-target-for-roche-holding-ltd-rog.html.
About Roche Holding
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.